NEUROCOV
Financiado
The pandemic within: tackling brain vulnerability in COVID19 at high resolution:...
The COVID19 pandemic has shown our health care fragility vis a vis novel pathogens, with a global disruption on societal welfare. Despite the towering success of vaccine development, lack of preparedness on integrative clinical an...
The COVID19 pandemic has shown our health care fragility vis a vis novel pathogens, with a global disruption on societal welfare. Despite the towering success of vaccine development, lack of preparedness on integrative clinical and molecular phenotyping has emerged with clarity and highlights the need to scale translational efforts for personalized prevention and therapy. Of particular concern are the long-term consequences of SARS-CoV-2 infection with high and rising prevalence of chronic manifestations referred to as Post-COVID. Among these the neurological and psychiatric complications stand out for frequency, lack of treatment and devastating impact of their effects at pandemic scale. Here, we tackle the cognitive and neurodegenerative complications of COVID-19, referred to as NeuroCOVID, as a ticking pandemic within the pandemic that requires an innovation leap across disciplines. We pursue a multi scalar approach that reaches from epidemiology and mechanistic interrogation of host/virus interplay at single cell resolution through predictive modelling all the way to validation of biomarkers and repurposed drugs. The aim is to anticipate and effectively manage personalized trajectories of NeuroCOVID vulnerability and their impact at population level. For this we leverage two leading national health registries and three clinical cohorts to characterize the phenotypic spectrum of NeuroCOVID, its risk factors and its socioeconomic burden at high definition. We pioneer innovative robotics to scale brain organoid modelling and combine it with single cell multiOMICs and AI analytics to dissect the principles of the individual host response and render experimentally actionable the authentic genetic backgrounds of differential SARS-CoV-2 sensitivity. Through a substantive engagement of patients’ collectives and health care stakeholders, upstream integration of innovative pipelines streamlines translation and operationalizes precision medicine for emerging medical needs.
ver más
Duración del proyecto: 63 meses
Fecha Inicio: 2022-05-20
Fecha Fin: 2027-08-31
Fecha Fin: 2027-08-31
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-05-20
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
Presupuesto
El presupuesto total del proyecto asciende a
8M€
Líder del proyecto
BUNDESMINISTERIUM FUER GESUNDHEIT
No se ha especificado una descripción o un objeto social para esta compañía.
359.84K€ |
Participante
168.75K€ |
Participante
197.64K€ |
Participante
180.36K€ |
Participante
536.92K€ |
Participante